Skip to content
Menu

Guggenheim Initiates Coverage On Disc Medicine with Buy Rating, Announces Price Target of $132

Benzinga Newsdesk 1 week ago

Analyst RatingsNewsInitiationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Guggenheim analyst Debjit Chattopadhyay initiates coverage on Disc Medicine (NASDAQ:IRON) with a Buy rating and announces Price Target of $132.

Guggenheim analyst Debjit Chattopadhyay initiates coverage on Disc Medicine (NASDAQ:IRON) with a Buy rating and announces Price Target of $132.

Read at benzinga.com